StockData
AstraZeneca PLC logo

AstraZeneca PLC

AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)

Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%

AstraZeneca Imfinzi (durvalumab) by Quarter

Imfinzi (durvalumab) — Emerging Markets product sales ($M) ($M)

QuarterlyAnnual

AstraZeneca Imfinzi (durvalumab): $211M in Q2 2026, up 38.8% from a year earlier. That is the highest of the 23 quarters on record here.

Latest, Q2 2026
211
Period ended Jun 30, 2026
Change on a year earlier
+38.8%
152 in Q2 2025
History
23 quarters
Since Q4 2020
Sources
23
Documents cited below

Where the Q2 2026 figure comes from

“|| Imfinzi | 1,854 | | 27 | | 27 | | 1,054 | | 25 | | 211 | | 39 | | 36 | | 398 | | 39 | | 34 | | 191 | | 10 | | 17”

Source: Form 6-K FY2026Q2 Earnings Release ↗

Reported in Form 6-K / 20-F Product Sales Table.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedImfinzi (durvalumab) — Emerging Markets product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026211+38.8%Form 6-K FY2026Q2 Earnings Release ↗
Q1 2026Mar 31, 2026187+31.7%Form 6-K FY2026Q1 Earnings Release ↗
Q4 2025Dec 31, 2025178+57.5%Form 6-K FY2025Q4 Earnings Release ↗
Q3 2025Sep 30, 2025169+40.8%Form 6-K FY2025Q3 Earnings Release ↗
Q2 2025Jun 30, 2025152+29.9%Form 6-K FY2025Q2 Earnings Release ↗
Q1 2025Mar 31, 2025142+10.1%Form 6-K FY2025Q1 Earnings Release ↗
Q4 2024Dec 31, 2024113+25.6%Form 6-K FY2024Q4 Earnings Release ↗
Q3 2024Sep 30, 2024120+37.9%Form 6-K FY2024Q3 Earnings Release ↗
Q2 2024Jun 30, 2024117+14.7%Form 6-K FY2024Q2 Earnings Release ↗
Q1 2024Mar 31, 2024129+59.3%Form 6-K FY2024Q1 Earnings Release ↗
Q4 2023Dec 31, 202390+42.9%Form 6-K FY2023Q4 Earnings Release ↗
Q3 2023Sep 30, 202387-3.3%Form 6-K FY2023Q3 Earnings Release ↗
Q2 2023Jun 30, 2023102+36.0%Form 6-K FY2023Q2 Earnings Release ↗
Q1 2023Mar 31, 202381+39.7%Form 6-K FY2023Q1 Earnings Release ↗
Q4 2022Dec 31, 202263-3.1%Form 6-K FY2022Q4 Earnings Release ↗
Q3 2022Sep 30, 202290+15.4%Form 6-K FY2022Q3 Earnings Release ↗

Breakdown

What makes up imfinzi (durvalumab)

Cite this data

StockData. (2026). AstraZeneca Imfinzi (durvalumab) ($M), quarterly Q4 2020–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med-imfinzi-em

See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.